Skip to content
Singlomics logo — Harnessing single-cell sequencing to create advanced antibod...

Singlomics

Harnessing single-cell sequencing to create advanced antibody therapies for infectious diseases and cancers

Founded 2020 Venture round Total: $410.00M Biotechnology, Health Care

General Information

Company Name Singlomics
Founded Year 2020
Founders / Decision Makers
Team member
Industries Biotechnology, Health Care
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Singlomics. To contact Singlomics, visit singlomics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Singlomics compare?

A PDF of Singlomics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Singlomics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Singlomics

Singlomics, founded in 2020, is a biotechnology startup utilizing single-cell sequencing technology to develop advanced antibody therapies for infectious diseases and cancers. With the slogan "Harnessing single-cell sequencing to create advanced antibody therapies for infectious diseases and cancers," Singlomics aims to revolutionize the treatment landscape. In July 2023, the company secured a noteworthy CNY10.00M Venture Round investment, indicative of investor confidence in its innovative approach. Singlomics operates within the Biotechnology and Health Care industries, positioning itself at the intersection of cutting-edge technology and pressing medical needs.

Business keywords: single-cell sequencing, antibody therapies, infectious diseases, cancer treatment, drug development, precision medicine, biopharmaceuticals, medical innovation

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round CNY10.00M -
01 Jul 2023
Venture Round Undisclosed 1
Tencent
03 Aug 2022
Series B CNY300.00M 9
Legend Capital, Huagai Capital +7
02 Feb 2022
Series A Undisclosed -
01 Dec 2020
Series A CNY100.00M -
01 Sep 2020

Singlomics Alternatives & Competitors

View All Alternatives
Singlomics vs

A clinical stage oncology company developing personalised medicine approaches to cancer; cellular &...

Post-IPO Equity
14 employees
Biopharma, Biotechnology
Singlomics vs

On a quest to leverage the power of single cell genomics to discover novel drug targets and precisio...

Acquired
2 employees
Biotechnology, Health Care
Singlomics vs
Onena Medicines
Onena Medicines Switzerland

AI-centric preclinical company discovering and developing novel biopharmaceuticals to treat cancer a...

9 employees
Biotechnology, Health Care

FAQ About Singlomics

Harnessing single-cell sequencing to create advanced antibody therapies for infectious diseases and cancers
Singlomics was founded in 2020.
Singlomics operates in Biotechnology and Health Care. Its work centres on single-cell sequencing, antibody therapies, infectious diseases and cancer treatment.
Singlomics has completed 5 funding rounds, raising a total of $410.00M. The latest funding stage is Venture round.
Top alternatives and competitors to Singlomics include Prescient Therapeutics, Celsius Therapeutics, Onena Medicines, MediQuest Therapeutics, VG Life Sciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Singlomics and Prescient Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Singlomics, https://bouncewatch.com/company/singlomics, updated 26 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout